Yersinia enterocolitica and Yersinia pestis

Bhunia, Arun K.

doi:10.1007/978-1-4939-7349-1_17

Cited by 2 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 6 , 7 Together with other antiphagocytic factors, F1 efficiently limits phagocytosis of Y. pestis by host cells and contributes to the extracellular survival of Y. pestis in vivo. 8 , 9 Not surprisingly, F1-negative Y. pestis strains have lower virulence. 5 , 10 However it is important to note that highly virulent F1-negative strains have been described.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Development of Anti-Yersinia pestis Human Antibodies with Features Required for Diagnostic and Therapeutic Applications

Lillo¹,

Velappan²,

Kelliher³

et al. 2020

ITT

View full text Add to dashboard Cite

Background: Yersinia pestis is a category A infective agent that causes bubonic, septicemic, and pneumonic plague. Notably, the acquisition of antimicrobial or multidrug resistance through natural or purposed means qualifies Y. pestis as a potential biothreat agent. Therefore, high-quality antibodies designed for accurate and sensitive Y. pestis diagnostics, and therapeutics potentiating or replacing traditional antibiotics are of utmost need for national security and public health preparedness. Methods: Here, we describe a set of human monoclonal immunoglobulins (IgG1s) targeting Y. pestis fraction 1 (F1) antigen, previously derived from in vitro evolution of a phagedisplay library of single-chain antibodies (scFv). We extensively characterized these antibodies and their effect on bacterial and mammalian cells via: ELISA, flow cytometry, mass spectrometry, spectroscopy, and various metabolic assays. Results: Two of our anti-F1 IgG (αF1Ig 2 and αF1Ig 8) stood out for high production yield, specificity, and stability. These two antibodies were additionally attractive in that they displayed picomolar affinity, did not compete when binding Y. pestis, and retained immunoreactivity upon chemical derivatization. Most importantly, these antibodies detected <1,000 Y. pestis cells in sandwich ELISA, did not harm respiratory epithelial cells, induced Y. pestis agglutination at low concentration (350 nM), and caused apparent reduction in cell growth when radiolabeled at a nonagglutinating concentration (34 nM). Conclusion: These antibodies are amenable to the development of accurate and sensitive diagnostics and immuno/radioimmunotherapeutics.

show abstract

Section: Introductionmentioning

confidence: 99%

“…8 (1 µL of a 1 mg/mL solution) in PBS plus 20% sucrose and 5% trehalose was deposited at the test region of a FF170HP nitrocellulose (NC)-membrane strip (2.5×0.5 cm, DCN). Mouse anti-human antibody (65 ng; Abcam) in the same buffer was deposited at the control region of the NC strip.…”

mentioning

confidence: 99%

Development of Anti-Yersinia pestis Human Antibodies with Features Required for Diagnostic and Therapeutic Applications

Lillo¹,

Velappan²,

Kelliher³

et al. 2020

ITT

View full text Add to dashboard Cite

show abstract

Yersiniosis with fever of unclear genesis

Kadochkina,

Salivontchik,

Mitsura

et al. 2024

jour

View full text Add to dashboard Cite

The article presents a clinical case of yersiniosis with fever of unclear genesis. For early diagnosis of yersiniosis, its adequate therapy and prevention of complications, it is necessary to take into account the dynamics of clinical manifes- tations and timely conduct specific diagnosis of the disease. Late diagnosis may be associated with the lack of vigilance of doctors with regard to this infection.

show abstract

Yersinia enterocolitica and Yersinia pestis

Cited by 2 publications

References 14 publications

<p>Development of Anti-<em>Yersinia pestis</em> Human Antibodies with Features Required for Diagnostic and Therapeutic Applications</p>

<p>Development of Anti-<em>Yersinia pestis</em> Human Antibodies with Features Required for Diagnostic and Therapeutic Applications</p>

Yersiniosis with fever of unclear genesis

Contact Info

Product

Resources

About